Minerva Neurosciences (NERV)
Develops roluperidone for negative symptoms of schizophrenia through a confirmatory Phase 3 trial.
Something off on this page? Send us feedback.
Develops roluperidone, a clinical-stage candidate for negative symptoms of schizophrenia. The business is centered on a global confirmatory Phase 3 trial after the FDA declined its prior NDA.
Develops roluperidone for negative symptoms in people diagnosed with schizophrenia. The clinical-stage program is the operating focus, rather than a portfolio of approved medicines.
A global confirmatory Phase 3 study began after the FDA issued a Complete Response Letter for the previous NDA. Any future resubmission depends on that additional study and its safety and efficacy record.
The lean development model relies on a small internal team, consultants, and outside companies for product-development functions. The program's regulatory path remains shaped by the FDA's requirement for an additional adequate, well-controlled study.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | Jefferies | Upgrade | Target: $5 | Target: $10 |
| Dec 1, 2025 | Jefferies | Target | Target: — | Target: $5 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $75.3M · Total debt $0 · Total assets $95.1M · Shareholders' equity −$201.6M
- Revenue
- $0
- Operating income
- −$10.6M
- Net income
- $17.5M
No dividends on record.
| Institutions | 88.87% | 42.43M shares | |
|---|---|---|---|
| 59 holders · as of Jun 30, 2026 | |||
| Insiders | 0.68% | 322.8K shares | |
| 3 holders · as of Aug 20, 2026 | |||
| Strategic holders | 9.13% | 4.36M shares | |
| 2 holders · as of May 15, 2026 | |||
| Other | 1.32% | 633.7K shares | |
| remainder | |||
47.75M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Federated Hermes, Inc.Institution | 9.78% | 4.67M | as of Jun 30, 2026 |
Coastlands Capital LPInstitution | 9.56% | 4.56M | filed Feb 20, 2026 |
Jupiter Topco LLCInstitution | 9.19% | 4.39M | as of Jun 30, 2026 |
Vivo Capital, LLCInstitution | 9.05% | 4.32M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 9.02% | 4.31M | filed May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Reviva Pharmaceuticals
Late-stage brilaroxazine program also pursuing schizophrenia
- Bristol-Myers Squibb
New oral schizophrenia therapy with a muscarinic mechanism
- Johnson & Johnson
Once-daily oral CAPLYTA for adult schizophrenia
- AbbVie
Oral atypical antipsychotic for schizophrenia
- Alkermes
Olanzapine/samidorphan treatment for adult schizophrenia
- Teva (ADR)
Long-acting subcutaneous risperidone for adult schizophrenia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Minerva Neurosciences | $3.63 | −4.72% | $177.5M | — | — | — | — |
| Reviva Pharmaceuticals | $0.4800 | −9.09% | $6.8M | — | — | — | — |
| Bristol-Myers Squibb | $61.61 | −1.03% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Johnson & Johnson | $270.13 | +0.35% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| AbbVie | $266.11 | +0.34% | $468.77B | 74.8 | 17.5 | 7.3 | +10.2% |
| Alkermes | $42.28 | −2.34% | $7.26B | 113.0 | — | 4.4 | +27.0% |
| Teva (ADR) | $39.46 | −0.15% | $46.03B | 65.9 | 14.1 | 2.7 | −0.8% |
| Median | 65.9 | 15.8 | 4.4 | +6.6% |